Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

New England Journal of Medicine

Volumn 344, Issue 26, 2001, Pages 1959-1965

  Ridker, Paul M ^a   Rifai, Nader ^a   Clearfield, Michael ^b   Downs, John R ^c   Weis, Stephen E ^b   Miles, J Shawn ^a   Gotto Jr , Antonio M ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; MEVINOLIN; STATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; CORONARY RISK; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS;

EID: 0035963529     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200106283442601     Document Type: Article

References (26)

1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
4. Maximizing the cost-effectiveness of lipid-lowering therapy
5. Using cost-effectiveness analysis to target cholesterol reduction
6. Summary of the second report of the National Cholesterol Education (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
7. Shattuck Lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
8. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
9. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
10. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
11. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
12. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
13. Long-term effects of pravastatin on plasma concentration of C-reactive protein
14. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
15. Pleiotropic effects of statins
16. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
17. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS)
18. Clinical efficacy of an automated high-sensitivity C-reactive protein assay
19. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS)
20. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
21. Atherosderosis - An inflammatory disease
22. Molecular bases of the acute coronary syndromes
23. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
24. Elevated C-reactive protein levels in overweight and obese adults
25. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?
26. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels